TCGA-E9-A229-01A-31R-A157-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- INTERFERON_GAMMA_RESPONSE+0.490
- UV_RESPONSE_DN+0.340
- APICAL_JUNCTION+0.250
- TGF_BETA_SIGNALING+0.250
- HEDGEHOG_SIGNALING+0.220
- ANGIOGENESIS+0.190
- PROTEIN_SECRETION+0.190
- MITOTIC_SPINDLE+0.180
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.540
- OXIDATIVE_PHOSPHORYLATION-0.530
- MYC_TARGETS_V1-0.410
- FATTY_ACID_METABOLISM-0.370
- ADIPOGENESIS-0.350
- HYPOXIA-0.320
- XENOBIOTIC_METABOLISM-0.310
- TNFA_SIGNALING_VIA_NFKB-0.300
- MTORC1_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2b1fa47d-360a-4b4a-aa11-23bdb025b559 | — | — | 0.859 |
| 2 | AUR-AG12-TTP1-A-1-0-R-A741-41 | — | A | 0.850 |
| 3 | GSM5359411 | — | — | 0.803 |
| 4 | SRR35579832 | — | A | 0.797 |
| 5 | MNG530 | — | — | 0.796 |
| 6 | de2e0c63-0c2d-43af-a006-7d84557a1c3c | — | — | 0.794 |
| 7 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.794 |
| 8 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.790 |
| 9 | C3L-02629 | — | cohortMD2 | 0.786 |
| 10 | SRR975558 | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |